Avacta advances pre|CISION oncology pipeline and extends cash runway with £10m raise

Avacta Group plc ( (GB:AVCT) ) has shared an update.

Avacta reported a strong start to 2026, with the U.S. IND for its Gen Two candidate AVA6103 cleared in January and the first patient dosed in the FOCUS-01 Phase 1 trial by the end of March. Preclinical data showed AVA6103’s sustained-release pre|CISION delivery achieved deeper, more selective tumor penetration versus a leading antibody drug conjugate, underscoring the potential competitiveness of Avacta’s platform.

The Gen One program AVA6000 benefited from positive regulatory feedback that removed the lifetime maximum dose limit, reflecting favorable cardiac safety and enabling clearer dose selection for future studies. Avacta also raised £10 million in an oversubscribed financing, extending its cash runway into early 2027 while retaining full ownership of its pipeline, as it prepares multiple clinical and preclinical data readouts this year that could reshape its standing in oncology and unlock partnering opportunities.

During 2026 the company plans to present updated preclinical and translational data for AVA6103 at the AACR congress and to release initial clinical data for the program in late H2. A further clinical update on AVA6000 is expected in H1, alongside Gen Three candidate selection for AVA6207 in H2, positioning the next three generations of pre|CISION assets for potential value inflection points that are closely watched by investors and potential collaborators.

The most recent analyst rating on (GB:AVCT) stock is a Hold with a £48.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.

Spark’s Take on AVCT Stock

According to Spark, TipRanks’ AI Analyst, AVCT is a Neutral.

Avacta Group plc’s overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While there is some progress in clinical programs, financial constraints and lack of partnerships remain significant risks. The stock’s valuation is unattractive due to negative earnings and no dividend yield.

To see Spark’s full report on AVCT stock, click here.

More about Avacta Group plc

Avacta Therapeutics, a clinical-stage biopharmaceutical company listed on AIM, develops oncology treatments using its proprietary pre|CISION platform. The technology is designed to activate highly potent payloads specifically within the tumor microenvironment via fibroblast activation protein, aiming to improve efficacy and reduce systemic toxicity in cancers such as salivary gland cancer and soft tissue sarcoma.

The company’s pipeline includes Gen One, Gen Two and Gen Three pre|CISION peptide drug conjugates, which are positioned as an alternative route into the XDC drug class beyond traditional antibody drug conjugates. Its lead candidate AVA6000 and second-generation asset AVA6103 are intended to demonstrate how tumor-targeted payload release can support higher dosing and better safety profiles, drawing interest from potential partners in oncology drug development.

Average Trading Volume: 1,847,390

Technical Sentiment Signal: Hold

Current Market Cap: £289.6M

Find detailed analytics on AVCT stock on TipRanks’ Stock Analysis page.